References
- Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302(13), 1437–1443 (2009).
- Drummond M, Jönsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur. J. Health Econ. 12, 263–271 (2011).
- Godman B, Gustafsson LL. A new reimbursement systems for innovative pharmaceuticals combining value-based and free market pricing. Appl. Health Econ. Health Policy 11, 79–82 (2013).
- Annemans L, Cleemput I, Hulstaert F, Simoens S. Valorising and creating access to innovative medicines in the European Union. Front. Pharmacol. 2(57), 1–6 (2011).
- Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU. Directorate general for internal policies, policy department A: Economic and scientific policy. European Parliament, Brussels, Belgium (2011).
- Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J. Good research practices in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report—part II. Value Health 13(1), 8–13 (2010).
- Ramsey FP. A contribution to the theory of taxation. Econ. J. 37, 47–61 (1927).
- Hay JW, Smeeding J, Carroll NV et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR drug cost task force report—part I. Value Health 13(1), 3–7 (2010).
- Danzon PM. Making sense of drug prices. Regulation 23(1), 56–63 (2000).
- OECD Health Policy Studies. Pharmaceutical Pricing Policies in a Global Market. OECD Publishing, Paris, France (2008).
- Vogler S, Habl C, Leopold C et al. Vienna, PPRI Report. Gesundheit österreich GmbH / Geschäftsbereich öBIG, Vienna (2008).
- Ridley DB. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 23(7), 651–658 (2005).
- Kaló Z, Docteur E, Moïse P. Pharmaceutical Pricing and Reimbursement Policies in Slovakia, OECD Health Working Paper, No. 31, p.14. OECD, Paris (2008).
- Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Affairs 25(2), 313–324 (2006).
- Danzon PM. Price discrimination for pharmaceuticals: welfare effects in the US and the EU. Int. J. Econ. Bus. 4(3), 301–321 (1997).
- Carlson JJ, Garrison LP, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J. Manag. Care Pharm. 15(8), 683–687 (2009).
- Towse A, Garrison LP. Can’t get no satisfaction? will pay for performance help? toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 28(2), 93–102 (2010).
- Coulton L, Annemans L, Carter R et al. Outcomes-based risk-sharing schemes – is there a potential role in the Asia-Pacific markets? Health Outcomes Res. Med. (3)4, e205-e219 (2012).
- Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96(3), 179–190 (2010).
- Kaló Z, Vokó Z. The role of risk sharing in drug funding (in Hungarian). LAM 20(3–4), 237–241 (2010).
- Orlewska E. Challenges and changes in the polish healthcare system. Soc. Econ. 33(3) 575–594 (2011).
- Garau M, Towse A, Danzon P. Pharmaceutical pricing in Europe: is differential pricing a win-win solution? occasional paper 11/01, office of health economics, London (2011).
- Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int. J. Health Care Finance Econ. 3(3), 183–205 (2003).
- Danzon PM, Towse A, Mulcahy AW: Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Aff. 30(3), 1529–1538 (2011).
Websites
- CEDD - Common European Drug Database. http://cedd.oep.hu/ (Accessed 1 August 2013)
- GAVI Alliance (Global Alliance for Vaccines and Immunization) www.gavialliance.org/ (Accessed 15 September 2011)
- Belgian Presidency Report. A call to make valuable innovative medicines accessible in the European Union (2010). www.ispor.org/congresses/Prague1110/documents/PlenaryII-Making-Innovative-Medicine-Accessible-in-the-EU.pdf (Accessed 1 August 2013)
- Transparency Directive, European Commission. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31989L0105:EN:HTML (Accessed 1 August 2013)